US FDA Clears Phase 3b Study of Caliway Biopharma's CBL-514 Fat-Reduction Drug
MT Newswires Live
Jul 06
Caliway Biopharmaceuticals (TPE:6919) said the US Food and Drug Administration has allowed its investigational new drug application for CBL-0303, a Phase 3b long-term follow-up study of CBL-514 for reducing abdominal subcutaneous fat, to proceed after the 30-day review period.
The study in the U.S. is expected to enroll about 300 participants who completed the company's pivotal Phase 3 trials to evaluate the long-term safety and durability of CBL-514's efficacy.
It will assess the drug's long-term safety and whether its effectiveness in reducing abdominal subcutaneous fat is maintained over time, with eligible participants also able to receive re-treatment.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.